Curanex Showcases Patient Case Study Highlighting Potential Of Phyto-N; Stock Up

Shares of Curanex Pharmaceuticals rose 6% after the company highlighted a compelling patient case study for its lead program Phyto-N targeting cancer cachexia and advanced cancer supportive care. The update is early, single-case evidence that may drive near-term investor interest but does not constitute pivotal clinical or regulatory data.

Analysis

Shares of Curanex Pharmaceuticals rose 6% after the company highlighted a compelling patient case study for its lead program Phyto-N targeting cancer cachexia and advanced cancer supportive care. The update is early, single-case evidence that may drive near-term investor interest but does not constitute pivotal clinical or regulatory data.